Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral polio vaccine
- Development stage
- Phase 4
- Lead developer
- Albert Sabin
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The oral polio vaccine (OPV) is a live attenuated viral vaccine administered orally to prevent poliomyelitis. Developed by Albert Sabin in 1961, OPV contains weakened forms of the three serotypes of poliovirus (types 1, 2, and 3), which induce immunity by replicating in the intestine and stimulating both mucosal and systemic immune responses. This mechanism not only protects vaccinated individuals but also helps interrupt person-to-person transmission of wild poliovirus within communities. OPV has played a critical role in reducing global cases of polio by over 99% since its introduction. However, rare cases of paralysis can occur due to reversion to neurovirulence or circulating vaccine-derived polioviruses (cVDPV). Novel versions such as nOPV2 have been developed for improved safety[1][3][5].
- Brand names
- Polio Sabin One and ThreePolio SabinOral Polio VaccineOPVSabin vaccine
- Other names
- Sabin vaccineTrivalent oral polio vaccineBivalent oral polio vaccineMonovalent oral polio vaccinenOPV2nOPV-2nOPV 2
02
Targets
PTBP1 (Polypyrimidine tract-binding protein 1)EIF4G1 (Eukaryotic translation initiation factor 4 gamma 1)
Beyond the preview
Go deeper on Oral polio vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oral polio vaccine.